Jakarta Anti-Aging Center Clinic , Jakarta , Indonesia .
Faculty of Medicine , Sriwijaya University , Palembang , Indonesia .
Einstein (Sao Paulo). 2023 Nov 17;21:eRW0387. doi: 10.31744/einstein_journal/2023RW0387. eCollection 2023.
The increasing popularity of cannabinoids for treating numerous neurological disorders has been reported in various countries. Although it reduces tetrahydrocannabinol psychoactivity, it helps patients tolerate higher doses and complements the anti-spasmodic effects of tetrahydrocannabinol. One of the most important potential of cannabinoids are related to its potential to help children with cerebral palsy, a contributor of lifelong disability. Therefore, this systematic review aimed to assess the efficacy and safety of medical cannabinoids in children with cerebral palsy.
This review adhered to The Preferred Reporting Items for Systematic Reviews and Meta-analysis 2020 guidelines. Seven databases, namely, Scopus, PubMed, EBSCO Host, ProQuest, Google Scholar, Semantic Scholar, and JSTOR, were used to identify relevant studies. Studies examining pediatric patients with cerebral palsy and reporting the efficacy and safety of medical cannabinoids through clinical trials, observational cross-sectional studies, or cohort designs were included. The outcomes of the studies included the efficacy of medical cannabinoids administered for spasticity, motor components, pain control, sleep difficulties, adverse effects, and seizure control.
Of 803 identified articles, only three met the inclusion criteria for data synthesis. One study exhibited a moderate risk-of-bias. A total of 133 respondents, mainly from Europe, were investigated. Overall effectiveness and safety were considered good. However, the results are inconsistent, especially regarding spasticity treatment variables.
The anti-spasticity, anti-inflammatory, and anti-seizure properties of cannabinoids might be beneficial for patients with cerebral palsy, although their effectiveness has not been widely studied. Further studies with larger sample sizes and various ethnicities are warranted. Prospero database registration: (www.crd.york.ac.uk/prospero) under ID CRD42022358383.
在不同国家，大麻素治疗多种神经疾病的应用越来越广泛。大麻二酚可降低四氢大麻酚的致幻活性，帮助患者耐受更高剂量，并增强四氢大麻酚的抗痉挛作用。大麻素最重要的潜力之一与帮助脑瘫患儿有关，脑瘫是导致终身残疾的原因之一。因此，本系统评价旨在评估医用大麻素治疗脑瘫患儿的疗效和安全性。
本综述遵循 2020 年《系统评价和荟萃分析的首选报告项目》指南。使用 Scopus、PubMed、EBSCOHost、ProQuest、Google Scholar、Semantic Scholar 和 JSTOR 等 7 个数据库，以识别相关研究。纳入评估脑瘫儿科患者，并通过临床试验、观察性横断面研究或队列设计报告医用大麻素疗效和安全性的研究。研究的结果包括医用大麻素治疗痉挛、运动障碍、疼痛控制、睡眠困难、不良反应和癫痫控制的疗效。
在 803 篇已识别的文章中，仅有 3 篇符合数据综合的纳入标准。其中 1 项研究存在中度偏倚风险。共调查了 133 名主要来自欧洲的应答者。总体有效性和安全性被认为是良好的。然而，结果不一致，特别是在痉挛治疗变量方面。
尽管医用大麻素的有效性尚未广泛研究，但它具有抗痉挛、抗炎和抗惊厥特性，可能对脑瘫患者有益。需要进行具有更大样本量和不同种族的进一步研究。Prospéro 数据库注册：（www.crd.york.ac.uk/prospero）登记号 CRD42022358383。
